Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks (NASDAQ: ZYME), a clinical-stage biotechnology company, has announced its participation in four major investor conferences in September 2025. The company, which focuses on developing novel biotherapeutics for cancer, inflammation, and autoimmune diseases, will engage in various activities at these events.
Management will attend Citi's Biopharma Back to School Conference (Sept 3), Wells Fargo Healthcare Conference (Sept 4), Cantor Global Healthcare Conference (Sept 5), and Morgan Stanley Annual Global Healthcare Conference (Sept 8). The schedule includes one-on-one meetings at all events and fireside chats at three of the conferences.
Zymeworks (NASDAQ: ZYME), una societ脿 biotecnologica in fase clinica, ha annunciato la sua partecipazione a quattro importanti conferenze per investitori nel settembre 2025. L'azienda, che sviluppa nuovi biofarmaci per cancro, infiammazione e malattie autoimmuni, prender脿 parte a diverse attivit脿 durante questi eventi.
La direzione sar脿 presente al Citi's Biopharma Back to School Conference (3 set), al Wells Fargo Healthcare Conference (4 set), al Cantor Global Healthcare Conference (5 set) e al Morgan Stanley Annual Global Healthcare Conference (8 set). Il programma prevede incontri one-to-one a tutti gli eventi e "fireside chats" in tre delle conferenze.
Zymeworks (NASDAQ: ZYME), una compa帽铆a biotecnol贸gica en fase cl铆nica, ha anunciado su participaci贸n en cuatro importantes conferencias para inversores en septiembre de 2025. La empresa, que desarrolla nuevos biof谩rmacos para c谩ncer, inflamaci贸n y enfermedades autoinmunes, participar谩 en varias actividades durante estos eventos.
La direcci贸n asistir谩 al Citi's Biopharma Back to School Conference (3 de sept), al Wells Fargo Healthcare Conference (4 de sept), al Cantor Global Healthcare Conference (5 de sept) y al Morgan Stanley Annual Global Healthcare Conference (8 de sept). El programa incluye reuniones individuales en todos los eventos y "fireside chats" en tres de las conferencias.
Zymeworks (NASDAQ: ZYME)電� 鞛勳儊 雼硠鞚� 氚旍澊鞓ろ厡韥� 須岇偓搿� 2025雲� 9鞗旍棎 鞐措Μ電� 雱� 臧滌潣 欤检殧 韴瀽鞛� 旎嵓霟办姢鞐� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞎�, 鞐检 氚� 鞛愱皜氅挫棴 歆堩櫂鞚� 鞙勴暅 鞁犼皽雲� 氚旍澊鞓れ箻耄岇牅毳� 臧滊皽頃橂姅 鞚� 須岇偓電� 頃措嫻 頄夓偓霌れ棎靹� 雼れ枒頃� 頇滊彊鞚� 歆勴枆頃� 鞓堨爼鞛呺媹雼�.
瓴届榿歆勋潃 Citi's Biopharma Back to School Conference(9鞗� 3鞚�), Wells Fargo Healthcare Conference(9鞗� 4鞚�), Cantor Global Healthcare Conference(9鞗� 5鞚�), Morgan Stanley Annual Global Healthcare Conference(9鞗� 8鞚�)鞐� 彀胳劃頃╇媹雼�. 鞚检爼鞐愲姅 氇摖 頄夓偓鞐愳劀鞚� 鞚茧寑鞚� 氙疙寘瓿� 靹� 臧滌潣 旎嵓霟办姢鞐愳劀 鞐措Μ電� 韺岇澊鞏挫偓鞚措摐 毂楈澊 韽暔霅橃柎 鞛堨姷雼堧嫟.
Zymeworks (NASDAQ: ZYME), une soci茅t茅 de biotechnologie en phase clinique, a annonc茅 sa participation 脿 quatre grandes conf茅rences pour investisseurs en septembre 2025. L'entreprise, qui d茅veloppe de nouveaux bioth茅rapeutiques contre le cancer, l'inflammation et les maladies auto-immunes, prendra part 脿 diverses activit茅s lors de ces 茅v茅nements.
La direction assistera au Citi's Biopharma Back to School Conference (3 sept.), 脿 la Wells Fargo Healthcare Conference (4 sept.), 脿 la Cantor Global Healthcare Conference (5 sept.) et 脿 la Morgan Stanley Annual Global Healthcare Conference (8 sept.). Le programme comprend des r茅unions individuelles 脿 tous les 茅v茅nements et des "fireside chats" lors de trois conf茅rences.
Zymeworks (NASDAQ: ZYME), ein biotechnologisches Unternehmen in klinischer Phase, hat seine Teilnahme an vier gro脽en Investorenkonferenzen im September 2025 angek眉ndigt. Das Unternehmen, das neuartige Biotherapeutika gegen Krebs, Entz眉ndungen und Autoimmunerkrankungen entwickelt, wird sich bei diesen Veranstaltungen an verschiedenen Aktivit盲ten beteiligen.
Das Management wird an der Citi's Biopharma Back to School Conference (3. Sept.), der Wells Fargo Healthcare Conference (4. Sept.), der Cantor Global Healthcare Conference (5. Sept.) und der Morgan Stanley Annual Global Healthcare Conference (8. Sept.) teilnehmen. Der Zeitplan umfasst pers枚nliche Einzelgespr盲che bei allen Veranstaltungen und "Fireside Chats" bei drei der Konferenzen.
- None.
- None.
VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences:
- Citi鈥檚 Biopharma Back to School Conference: Zymeworks鈥� management will participate in one-on-one meetings on September 3 in Boston, MA.
- Wells Fargo Healthcare Conference: Zymeworks鈥� management will participate in one-on-one meetings and a fireside chat on September 4 at 4:30 pm Eastern Time (ET) in Boston, MA.
- Cantor Global Healthcare Conference: Zymeworks鈥� management will participate in one-on-one meetings and a fireside chat on September 5 at 8:35 am ET in New York, NY.
- Morgan Stanley Annual Global Healthcare Conference: Zymeworks鈥� management will participate in one-on-one meetings and a fireside chat on September 8 at 3:20 pm ET in New York, NY.
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks鈥� mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company鈥檚 complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company鈥檚 proprietary Azymetric鈩� technology. Zymeworks has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab has received accelerated approval from the U.S. FDA, conditional approval from the NMPA in China, and conditional marketing authorization from the European Commission for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. It is the first and only dual HER2-targeted bispecific antibody approved for this indication in the U.S., Europe, and China. Zanidatamab is also being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are actively recruiting, and ZW251 is expected to enter clinical trials in 2025. In addition to Zymeworks鈥� pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit and follow on X.
Investor inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
[email protected]
Media inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
[email protected]
FAQ
When is Zymeworks (ZYME) presenting at the Wells Fargo Healthcare Conference 2025?
Which investor conferences is Zymeworks (ZYME) attending in September 2025?
What type of company is Zymeworks (ZYME)?
Where will the Zymeworks (ZYME) conference presentations take place?
